Phosphoproteomics of in vivo resistance to EGFR-targeted therapy in lung cancer cells

ABSTRACT: Mass spectrometry-based quantitative proteomics profiling of in vivo signaling changes in 41 therapy resistant (osimertinib or EGFR/Met bispecific antibody treament) tumors from four xenograft NSCLC models.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

SUBMITTER: Kristina Bennet Emdal  

LAB HEAD: Forest White

PROVIDER: PXD006114 | Pride | 2017-08-28

REPOSITORIES: Pride